Cellectis S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering

ST. PAUL, Minn. & NEW YORK–(BUSINESS WIRE)– Regulatory News:

Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) and Calyxt, Inc. announced
today the pricing of Calyxt’s initial public offering of 7,000,000
shares of its common stock at the initial public offering price of $8.00
per share (the “Offering”). The number of shares in the Offering
represents an increase of 939,394 shares from the 6,060,606 shares
previously disclosed, and the initial public offering price represents a
decrease from the previously disclosed estimated price range of $15.00
to $18.00 per share. In addition, Calyxt granted the underwriters for
the Offering an option to purchase up to 1,050,000 additional shares of
Calyxt’s common stock at the initial public offering price less the
underwriting discount. The Offering is expected to close on or about
July 25, 2017, subject to customary closing conditions. Calyxt’s shares
of common stock have been approved for listing on NASDAQ and are
expected to begin trading under the ticker symbol “CLXT” on July 20,
2017.

Calyxt is Cellectis’ gene editing agriculture company. Prior to the
Offering, Cellectis owned 100% of Calyxt’s outstanding shares of common
stock. Immediately following completion of the Offering after giving
effect to the 2,500,000 shares of common stock Cellectis purchased in
the Offering, Cellectis will own approximately 83.1% of Calyxt’s
outstanding shares of common stock (or 79.9% if the underwriters
exercise their option to purchase additional shares in full).

Citigroup, Jefferies and Wells Fargo Securities are acting as joint
book-running managers for the proposed offering. BMO Capital Markets and
Ladenburg Thalmann are acting as co-managers.

A registration statement on Form S-1 relating to these securities was
declared effective by the U.S. Securities and Exchange Commission. The
Offering is being made only by means of a prospectus. A copy of the
final prospectus relating to this Offering, when available, may be
obtained from Citigroup Global Markets Inc., c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone
at (800) 831-9146, Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by
telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com,
or Wells Fargo Securities, Attention: Equity Syndicate Department, 375
Park Avenue, New York, New York, 10152, at (800) 326-5897 or by email at cmclientsupport@wellsfargo.com.

The final prospectus will also be available at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

This press release contains inside information within the meaning of
Article 7(1) of the EU Market Abuse Regulation.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170719006412/en/